Thomas Darcy Net Worth

Thomas Darcy biography

Thomas E. Darcy serves as Director of the Company. Mr. Darcy served as our Chief Financial Officer from August 2007 to February 2017 and as our Executive Vice President from August 2007 to May 2017. Mr. Darcy is a co-founder of Tocagen. Prior to joining us, Mr. Darcy served for over five years as Executive Vice President and Chief Financial Officer of Science Applications International Corporation (“SAIC”), a publicly-held science and technology company. Mr. Darcy also served as a director and chairman of the audit committee of McAfee, Inc., a publicly-held technology company, for over three years until its sale to Intel Corporation in February 2011. Mr. Darcy also currently serves as a director and chairman of the audit committee of Lytx, Inc., a privately-held technology company. Prior to SAIC, he was a Partner in the accounting firm of PricewaterhouseCoopers LLP, where he served as the Managing Partner of both the West and Southwest Region Audit and Business Advisory Service Technology practices, as well as the Managing Partner of the San Diego office. Mr. Darcy is a Certified Public Accountant (inactive) in the state of California and graduated from San Diego State University with a B.S. in Accounting.

What is the salary of Thomas Darcy?

As the Director of Tocagen, the total compensation of Thomas Darcy at Tocagen is $85,495. There are 1 executives at Tocagen getting paid more, with Fairooz Kabbinavar having the highest compensation of $1,139,660.

How old is Thomas Darcy?

Thomas Darcy is 70, he's been the Director of Tocagen since 2017. There are no older and 5 younger executives at Tocagen.

What's Thomas Darcy's mailing address?

Thomas's mailing address filed with the SEC is 3030 Bunker Hill St #230, San Diego, CA 92109, USA.

Insiders trading at Tocagen

Over the last 7 years, insiders at Tocagen have traded over $0 worth of Tocagen stock and bought 339,950 units worth $1,867,749 . The most active insiders traders include Faheem Hasnain, Steven Michael Oliveira és Franklin M Berger. On average, Tocagen executives and independent directors trade stock every 99 days with the average trade being worth of $2,157,169. The most recent stock trade was executed by Steven Michael Oliveira on 14 April 2020, trading 74,301 units of TOCA stock currently worth $88,418.

What does Tocagen do?

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.

Tocagen executives and stock owners

Tocagen executives and other stock owners filed with the SEC include:

• Fairooz Kabbinavar,
  Senior Vice President, Clinical Development
• Thomas Darcy,
  Director
• Peter Rahmer,
  IR Contact Officer
• Donald Williams,
  Director
• Patricia Walker,
  Director
• Steven Kornfeld,
  Director
• Lawrence Eichenfield,
  Director
• Antony Riley,
  Chief Financial Officer
• Paul Wagner,
  Chairman of the Board, President, Chief Executive Officer
• Steven Michael Oliveira,
  10% owner
• Asha Das,
  SVP & Chief Medical Officer
• Franklin M Berger,
  Director
• Paul Schimmel,
  Director
• Dennis N Berman,
  
• Harry E Gruber,
  President, Science&Innovation
• Douglas Jolly,
  EVP, Research & Pharm Devel
• Martin J Duvall,
  Chief Executive Officer
• Faheem Hasnain,
  Director
• Mark G Foletta,
  EVP & Chief Financial Officer
• David Ross Parkinson,
  Director
• Lori Anne Kunkel,
  Director